Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.

Thanks to David Krumholtz of "The Santa Clause" fame, we've gotten our very first glimpse at the official logo for next year's "Supergirl: Woman of Tomorrow"... or perhaps just "Supergirl"?

Drake University and Des Moines Area Community College could be close to a settlement agreement in a hotly contested legal battle over the schools' logos and trademarks. New court records show a ...

His infamous sketch in the back of a yellow cab became the most imitated logo in history—and cities are still copying it today. In the summer of 1977, New York City was burning. A 25-hour ...

The logos of Big Tech companies and key associations were featured prominently Monday at the White House Easter Egg Roll, offering an unprecedented scene and use of the grounds to promote private ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The Zacks Consensus Estimate for revenues is pegged at $3.25 billion, while the ...

It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma ...